Post by Giuseppe Privitera

Excited to share the results of the LONG-LIVE study 🎉 the long-term extension of our multicenter IG-IBD LIVE project on vedolizumab We followed 782 patients for up to 7 years (4,324 patient-years! 📈) 📊 Key findings: 🔹 29.4% of patients experienced a major adverse clinical outcome (surgery, hospitalization, or serious adverse event) at 5 years 🔹 Surgery occurred in ~1 in 5 patients (23.4%) 🏥 🔹 Non-surgical hospitalizations were more frequent in CD than UC 👵👴 Elderly patients had a higher risk of major adverse clinical outcomes, but NOT of serious adverse events, supporting the use of vedolizumab across age groups 💪 A big team effort from the IG-IBD network, providing real-world "hard outcome" data over one of the longest follow-up periods reported to date. Huge thanks to all co-authors 🙏 Flavia Palumbo Fabio Macaluso Lucrezia Laterza Veronica Pardi Anna Viola Daniele Noviello Brigida Barberio Chiara Ricci paola balestrieri Maria Cappello Giovanni Maconi Renato Sablich Angela Variola Raffaele Bennato Luca Pastorelli Laurino Grossi Davide Giuseppe Ribaldone Andrea Buda Fabrizio Bossa Antonio Di Sario Benedetto Neri giammarco mocci Cristiano Pagnini Beatrice Principi Marina Coletta Carlo Petruzzellis Silvia Mazzuoli Stefano Festa agnese miranda Cristina Bezzio Libera Fanigliulo Giulia Rocco Elisabetta Dal Pont Rocco Spagnuolo Edoardo Savarino Flavio Caprioli Walter Fries Linda Ceccarelli Franco Scaldaferri Ambrogio Orlando anna testa Daniela Pugliese Alessandro Armuzzi #IBD #Vedolizumab #IGIBD #RealWorldEvidence https://lnkd.in/eAdHTmdm